Pelacarsen managed access for serious illnesses
Treatments studied
Part of Heart & circulation clinical trials.
This program provides access to pelacarsen (TQJ230) for patients with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial. It aims to offer potential benefit when standard therapies are not suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor must request the drug for you.
- You have a serious or life-threatening condition with no good alternative treatments.
- You cannot take part in a clinical trial or continue one you were in.
- The possible benefits of the drug are likely to outweigh the risks.
- The drug's use must be allowed by local laws and not conflict with any ongoing Novartis clinical trials.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called pelacarsen for people with very high Lp(a) (a type of cholesterol) and existing heart or blood vessel disease. It aims to see if adding pelacarsen to your current cholesterol treatment can lower your Lp(a) levels further.
This trial is for people who have already finished taking pelacarsen in a previous study. It offers continued access to the drug and checks long-term safety.
This study follows patients who completed an earlier pelacarsen trial to check if the treatment remains safe and well-tolerated over time. Pelacarsen is an experimental medicine being tested for heart and cholesterol health.
This study tests whether pelacarsen, an experimental medicine, can safely lower Lp(a)—a type of cholesterol linked to heart disease—in people who recently had a heart attack. The goal is to see if lowering Lp(a) can help prevent future heart problems.
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Atherosclerotic Cardiovascular Disease (ASCVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.